Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654841 | 0.89 | GCK (0.60) | GCKKMT2ACNR2EPHX2PTGS2 | |
| SCHEMBL1581747 | 0.89 | GCK (0.60) | GCKKMT2ACNR2EPHX2PTGS2 | |
| SCHEMBL2666200 | 0.88 | GCK (0.59) | GCKKMT2ACNR2EPHX2PTGS2 | |
| SCHEMBL1582235 | 0.88 | GCK (0.58) | GCKKMT2ACNR2EPHX2PTGS2 | |
| SCHEMBL9072639 | 0.86 | GCK (0.57) | GCKKMT2ACNR2EPHX2PTGS2 | |
| SCHEMBL1581861 | 0.86 | GCK (0.57) | GCKKMT2ACNR2EPHX2PTGS2 | |
| SCHEMBL1107322 | 0.86 | GCK (0.57) | GCKKMT2ACNR2EPHX2PTGS2 | |
| SCHEMBL1581698 | 0.86 | GCK (0.60) | GCKKMT2ACNR2EPHX2PTGS2 | |
| SCHEMBL15828006 | 0.80 | GCK (0.59) | GCKKMT2ACNR2EPHX2PTGS2 | |
| SCHEMBL2662321 | 0.76 | GCK (1.00) | GCKKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | GCK 2/4885KMT2A 2344/4885CNR2 2922/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | GCK 2/4885KMT2A 2260/4885CNR2 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.